Search research articles
Contact Us
Filters
Showing results (801-810 of 932) with videos related to
Page
of 94
Sort By:
Clinical Genitourinary Cancer
|
August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Vishal Navani, J Connor Wells, Devon J Boyne, et al.
Cancer
|
January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
Rana R McKay, Wanling Xie, Xiaoyu Yang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Jeffrey Graham, John Connor Wells, Shaan Dudani, et al.
European Urology
|
January 27, 2023
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
Matthew S Ernst, Vishal Navani, J Connor Wells, et al.
Clinical Genitourinary Cancer
|
October 14, 2025
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Audreylie Lemelin, David Maj, Kosuke Takemura, et al.
Nature Cancer
|
March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
Maishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Cancer
|
February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database
Kripa Guram, Jiaming Huang, Christian Mouchati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A McGregor, Rana R McKay, David A Braun, et al.
The Journal of Clinical Investigation
|
July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma
Shuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Page
of 94
Search research articles
Search
Showing results (801-810 of 932) with videos related to
Sort By:
Page
of 94
Clinical Genitourinary Cancer
|
August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Vishal Navani, J Connor Wells, Devon J Boyne, et al.
Cancer
|
January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
Rana R McKay, Wanling Xie, Xiaoyu Yang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Jeffrey Graham, John Connor Wells, Shaan Dudani, et al.
European Urology
|
January 27, 2023
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
Matthew S Ernst, Vishal Navani, J Connor Wells, et al.
Clinical Genitourinary Cancer
|
October 14, 2025
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Audreylie Lemelin, David Maj, Kosuke Takemura, et al.
Nature Cancer
|
March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
Maishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Cancer
|
February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database
Kripa Guram, Jiaming Huang, Christian Mouchati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A McGregor, Rana R McKay, David A Braun, et al.
The Journal of Clinical Investigation
|
July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma
Shuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Page
of 94